Know Cancer

or
forgot password

Phase II Trial of CLAG-M in Relapsed ALL


Phase 2
N/A
N/A
Open (Enrolling)
Both
Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitts Leukemia/Lymphoma, Chronic Myelogenous Leukemia

Thank you

Trial Information

Phase II Trial of CLAG-M in Relapsed ALL


Patients will receive standard dose CLAG-M (cladribine, cytarabine, mitoxantrone,
filgrastim). Standard support care will be given. Efficacy will be assessed through bone
marrow examinations and blood tests.


Inclusion Criteria:



- Relapsed or refractory acute lymphoblastic leukemia,

- Burkitts leukemia/lymphoma,

- Lymphoid blastic CML,

- Lymphoblastic lymphoma.

Type of Study:

Interventional

Study Design:

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Complete remission percentage

Outcome Time Frame:

1 month

Safety Issue:

No

Principal Investigator

Karen Seiter, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

New York Medical College

Authority:

United States: Institutional Review Board

Study ID:

L-10,442

NCT ID:

NCT01513603

Start Date:

January 2012

Completion Date:

January 2014

Related Keywords:

  • Acute Lymphoblastic Leukemia
  • Lymphoblastic Lymphoma
  • Burkitts Leukemia/Lymphoma
  • Chronic Myelogenous Leukemia
  • Burkitt Lymphoma
  • Leukemia
  • Leukemia, Lymphoid
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma
  • Leukemia, Myeloid
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive
  • Lymphoma
  • Lymphoma, Non-Hodgkin

Name

Location
Westchester Medical Center/New York Medical College Valhalla, New York  10595